Molecular sequencing using the Illumina TruSight Oncology 500 panel revealed a fusion between EML4 and ALK (V5, EML4 exon 2—ALK exon 20), as well as high NTRK1 RNA expression, gain of function mutation in oncogene TERT, biallelic loss of tumour suppressor CDKN2A and CDKN2B, microsatellite stable and low tumour mutation burden (0.8 mut/Mb). This evidence concerns the gene CDKN2A and neoplasm.